Ophthalmic Solution articles & resources on Made-in-China.com

US FDA Granted Final Approval for The Company's Abbreviated New Drug Application

Jan 23, 2014

Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for Bromfenac ...

Tags: Health, Medicine

Santen Pharmaceutical Has Introduced TAPROS MINI Ophthalmic Solution 0.0015%

Oct 15, 2013

Santen Pharmaceutical, a manufacturer of ophthalmic and anti-rheumatic pharmaceuticals, has introduced TAPROS MINI ophthalmic solution 0.0015%, indicated for glaucoma and ocular hypertension. TAPROS MINI ophthalmic solution contains ...

Tags: Santen Pharmaceutical, Mini Ophthalmic Solution

INSV Has Reported The US District Court Upheld All Four of The Patents Protecting AzaSite

Oct 10, 2013

InSite Vision Incorporated (INSV) has reported that the US District Court for the District of New Jersey upheld all four of the patents protecting AzaSite, an azithromycin 1% ophthalmic solution, in a patent infringement lawsuit against ...

Tags: Sandoz, Medicine

InSite Vision Has Again Secured The Development Rights

Jun 25, 2013

InSite Vision has again secured the development rights for zithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra, from Merck's subsidiary, Inspire Pharmaceuticals, in North America. According to the deal, a joint development ...

Tags: North America, InSite Vision, AzaSite Xtra

The FDA Has Approved R-Tech Ueno's Novel Ophthalmic Solution

May 23, 2013

The FDA has approved R-Tech Ueno's novel ophthalmic solution, developed using Novozymes Biopharma's recombinant human albumin, to enter into Phase I/II trials. R-Tech is trialing RU-101 ophthalmic solution as a severe dry eye therapy. ...

Tags: Ophthalmic Solution, Phase I/II Trials

R-Tech Ueno Has Begun Enrolling Patients with Severe Dry Eye

May 22, 2013

R-Tech Ueno has begun enrolling patients with severe dry eye in Phase I/II study of recombinant human serum albumin-containing ophthalmic solution (development code: RU-101) in US. The two-stage trial is performed as a double masking test ...

Tags: R-Tech, Dry Eye Study